Introduction
The bactericidal activity of -lactam antibiotics is determined by the time that concentrations in tissue and serum exceed a certain threshold and higher concentrations do not produce added efficacy. If antibiotic concentrations decrease to below this threshold, bacterial growth is resumed immediately 1 since there is no significant postantibiotic effect, as seen with aminoglycosides. 2 Therefore it is vital for the efficacy of -lactams that the dosing regimen maintains adequate serum concentrations for the entire course of therapy.
Dosage regimens for drugs used in critically ill patients are often based on pharmacokinetic data obtained in healthy patients. However, drug pharmacokinetics are markedly altered during critical illness 3 which may lead to drug accumulation and toxicity, or loss of efficacy as a result of subtherapeutic drug concentrations. 4 The limited data available on the pharmacokinetics of ceftazidime in the critically ill suggest there are differences from healthy subjects and therefore the current dosing practice may not be appropriate in such patients. 5, 6 We measured serum concentrations of ceftazidime in ten critically ill patients to calculate the pharmacokinetics of ceftazidime and to determine if the current recommended dosing practice maintains adequate serum concentrations for antibacterial efficacy in this group of patients.
Materials and methods
The study was performed in the 16 University of Hong Kong. The patients' clinical condition precluded them from giving their own informed consent and this was therefore obtained from the most senior available relative. Ten adult patients in the Intensive Care Unit who required ceftazidime according to usual clinical practice were enrolled. Patients were excluded who had a history of allergy to cephalosporins, renal impairment (as defined by a serum creatinine concentration of 120 mol/L) or were already receiving ceftazidime. Demographic and clinical data, APACHE II score, number of organ system failures, 7 plasma biochemistry, renal and liver function tests, complete blood picture, arterial blood gases and coagulation studies were recorded.
The patients were prescribed ceftazidime at the recommended maximum dose of 2 g every 8 h, with each 2 g given in an iv infusion over 30 min. Arterial blood samples were collected at 0, 5, 10, 20 and 30 min during the infusion and then, following completion of the infusion, at 31, 32, 34, 37, 40, 50, 60, 90, 120, 150, 240, 360 and 480 min. Blood specimens were centrifuged and plasma stored at 70°C for later analysis. An 8 h urine collection was performed during the period of blood sampling for calculation of creatinine clearance. Ceftazidime 2 g every 8 h was then continued for a full course. An additional trough specimen was taken on day 3.
Plasma ceftazidime assays were performed by HPLC as described previously. 8 The calibration curve for the assay was linear over the range 1-500 mg/L (r 0.9994). The within-day coefficient of variation at 50 mg/L was 1.6%.
Pharmacokinetic modelling using a two-compartment model was performed with MK MODEL version 5.02 (Biosoft, Cambridge, UK). Ninety-five percent confidence intervals (95% CIs) were calculated for elimination halftime (t 1/2 ), volume of distribution at steady state (V ss ) and total body clearance (Cl) to enable comparison with published data. Multiple regression analysis of ceftazidime clearance, half-time and volume of distribution against clinical parameters of APACHE II score, organ failure score, plasma bilirubin, albumin and creatinine clearance were performed using Stat View II (Abacus Concepts Inc., Berkeley CA, USA). P values of 0.05 were considered significant.
The pharmacokinetic data were used to derive an alternative dosing regimen using a loading dose and continuous infusion. The performance of this regimen was tested by modelling predicted plasma ceftazidime concentrations in each patient using their own pharmacokinetic variables.
Results
Eight males and two females were enrolled. Demographic and clinical details are shown in Table I . Figure 1 shows individual plasma ceftazidime concentration curves. Pharmacokinetic variables and trough ceftazidime concentrations (at 8 h and 3 days) for each patient are shown in Table II . Trough data are incomplete for patient 1 (sampling error), patient 3 (antibiotic changed because of bacterial resistance) and patient 4 (died before completion of the study).
All patients had plasma creatinine concentrations within the normal range at study entry. However, patients 4 and 8 developed renal impairment during the period of blood sampling as shown by creatinine clearances of 20 and 39 mL/min, respectively. Because we intended to study patients with normal renal function, those patients' pharmacokinetic parameters were excluded from further analysis. Mean pharmacokinetic variables for the remaining eight patients are shown in Table III , along with previously published pharmacokinetic data for ceftazidime. [9] [10] [11] [12] The 95% CIs were 0.21-0.24 L/kg for V ss ; 1.4-1.8 mL/min/kg for Cl; and 103-135 min for t 1/2 . There was no correlation between ceftazidime clearance, elimination half-time and volume of distribution and clinical parameters such as APACHE II score, organ failure score, plasma bilirubin and albumin. There was a correlation between creatinine clearance and ceftazidime clearance (see Figure 2 ). Predicted plasma ceftazidime concentrations for each individual patient using a loading dose of 1 g followed by the usual dose of 2 g every 8 h given as a continuous infusion (i.e. 250 mg/h) are shown in Figure 3 . Modelling predicts that this regimen would maintain plasma concentrations above 8 mg/L in all patients and above 40 mg/L in six of the ten patients (see Figure 3) . Plasma concentrations in three of the remaining patients would decrease to minima of 29, 33 and 35 mg/L, respectively, at 7 days and one patient would have a minimum of 38 mg/L at 73 min but would be maintained above 40 mg/L from 216 min. 
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Discussion
Ceftazidime is a third-generation cephalosporin with activity against most of the Enterobacteriaceae, including Pseudomonas aeruginosa. 13 It is commonly used in proven pseudomonal infections and has been recommended as empirical therapy in ventilator-associated pneumonia, given the high incidence of P. aeruginosa in such infections.
14 Failure of therapy is common in P. aeruginosa infections, with development of antibiotic resistance in vivo a major problem. 15 The bactericidal efficacy of -lactam antibiotics correlates with the time the antibiotic concentration is maintained above the MIC. [16] [17] [18] However, the optimal time for which the concentration should exceed the MIC is unknown. 19 Vogelman et al. 17 suggested that the dosing regimen should maintain plasma concentrations above the MIC for at least 50% of the time but, for maximal efficacy, it should be above the MIC throughout the dosing interval.
Fantin et al. 18 showed in a rabbit model of P. aeruginosa endocarditis that ceftazidime resistance resulted if antibiotic concentrations fell below the MIC for 61% of the dosing interval. They suggested that dosing regimens that resulted in serum concentrations constantly above the MIC may prevent emergence of resistance and improve antibiotic efficacy.
Mouton & den Hollander 1 demonstrated in an in-vitro model of intermittent bolus administration of ceftazidime that regrowth of P. aeruginosa occurred between boluses. In their model, a level above the MIC was not adequate and a sustained concentration of [4] [5] MIC was required to inhibit growth. Given the published MIC for P. aeruginosa of 2-8 mg/L, 15, 20, 21 this would imply that plasma concentrations of 10-40 mg/L are required for efficacy against that organism. From Figure 1 it can be seen that only one of the ten patients we studied achieved a concentration of 40 mg/L throughout the dosing interval, despite the fact that we used the maximum recommended dose of ceftazidime. Lower doses of ceftazidime which are commonly prescribed (e.g. 1 g every 8 h) would result in even lower concentrations for a greater proportion of the dosing interval. In tissues the ceftazidime concentrations achieved would be even lower. 16, 22 Ceftazidime is not metabolized, has low protein binding and is eliminated nearly entirely by glomerular filtration. 23 We attempted to exclude from this study patients with grossly impaired renal function to enable analysis for other factors which could potentially modify ceftazidime pharmacokinetics in critical illness. Despite the relatively narrow range of creatinine clearances in our patients we were still able to demonstrate a correlation between creatinine clearance and drug clearance (see Figure 2) . We were unable to show correlation between any other clinical parameter and the pharmacokinetic variables of ceftazidime.
Plasma t 1/2 , V ss and Cl in our critically ill patients did not differ from previously reported data in healthy volunteers (see Table III ). However, there was wide interpatient variability in pharmacokinetics which resulted in very variable plasma ceftazidime concentrations, with the concentrations in three of the ten patients studied falling below the MIC for P. aeruginosa of 8 mg/L (see Figure 1 ). There was no clinical parameter predictive of which patients would have increased drug clearance and hence low plasma concentrations of ceftazidime. Whilst routine monitoring of plasma ceftazidime concentrations would detect patients with low levels, such monitoring is not readily available in most centres and would not prevent suboptimal concentrations in the critical, early phase of infection. A loading dose followed by a continuous infusion should prevent low antibiotic concentrations as demonstrated by pharmacokinetic modelling using data from our patients (see Figure 3) . We believe this is the dosing regimen of choice but it awaits prospective, in-vivo evaluation.
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In summary, plasma concentrations of ceftazidime administered by an intermittent bolus regimen are very variable and trough levels may fall too low for safety in critical infections, even when using the maximum recommended dose. This may result in treatment failure and the emergence of antibiotic resistance. Pharmacokinetic modelling shows that a loading dose followed by continuous infusion should overcome these problems.
